Home » Stocks » OYST

Oyster Point Pharma, Inc. (OYST)

Stock Price: $19.81 USD -0.21 (-1.05%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 513.27M
Revenue (ttm) n/a
Net Income (ttm) -70.52M
Shares Out 24.13M
EPS (ttm) -21.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $19.81
Previous Close $20.02
Change ($) -0.21
Change (%) -1.05%
Day's Open 19.82
Day's Range 19.23 - 20.49
Day's Volume 61,486
52-Week Range 17.24 - 39.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

GlobeNewsWire - 1 week ago

PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on th...

GlobeNewsWire - 2 weeks ago

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET

GlobeNewsWire - 1 month ago

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

GlobeNewsWire - 2 months ago

The NDA submission is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease. The NDA submission is based ...

GlobeNewsWire - 2 months ago

Industry veterans in ophthalmology will lead and expand the company's R&D and clinical efforts Industry veterans in ophthalmology will lead and expand the company's R&D and clinical efforts

GlobeNewsWire - 2 months ago

Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021 Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021

GlobeNewsWire - 3 months ago

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

Seeking Alpha - 3 months ago

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET

GlobeNewsWire - 4 months ago

Ali Behbahani, M.D. takes on role of Chairperson of the Board

GlobeNewsWire - 5 months ago

PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commerciali...

Seeking Alpha - 6 months ago

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

PRINCETON, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

GlobeNewsWire - 6 months ago

Conference Call and Webcast Scheduled for August 5, 2020, 8:30 am ET Conference Call and Webcast Scheduled for August 5, 2020, 8:30 am ET

Zacks Investment Research - 9 months ago

Oyster Point (OYST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-i...

GlobeNewsWire - 9 months ago

PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-i...

GlobeNewsWire - 9 months ago

PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-i...

Seeking Alpha - 9 months ago

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 ...

GlobeNewsWire - 10 months ago

ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020

Seeking Alpha - 11 months ago

Oyster Point Pharma: This Is An Attractive Dry Eye Disease Player For 2020

Seeking Alpha - 11 months ago

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

PRINCETON, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

About OYST

Oyster Point Pharma, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Industry
Biotechnology
IPO Date
Oct 31, 2019
CEO
Dr. Jeffrey Nau Ph.D., MMS
Employees
30
Stock Exchange
NASDAQ
Ticker Symbol
OYST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OYST stock is "Buy." The 12-month stock price forecast is 65.00, which is an increase of 228.12% from the latest price.

Price Target
$65.00
(228.12% upside)
Analyst Consensus: Buy